CeriBell (CBLL) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$102.0M

Revenue (quarter)

$28.1M

Revenue growth (year over year)

+32.54%

Gross profit (trailing twelve months)

$90.6M

Gross margin

88.90%

Net income (trailing twelve months)

−$66.0M

Net income (quarter)

−$19.3M

Net income growth (year over year)

−41.23%

Net margin

−64.73%

Return on equity

−43.93%

EPS (trailing twelve months)

−$1.76

Book value per share

$3.36

P/E (trailing twelve months)

—

Price to book

7.82

Debt to assets

22.86%

Payout ratio

—

Dividend yield

—

Company profile

CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.

• Is CeriBell (CBLL) profitable?

  No. CeriBell reported a net loss of $66.0M over the trailing twelve months.

• How much revenue does CeriBell (CBLL) make?

  CeriBell generated $102.0M in revenue over the trailing twelve months, up 32.54% year over year.

• How do I buy stock in CeriBell (CBLL)?

  CBLL trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.